BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011; 3(7): 198-204 [PMID: 21866251 DOI: 10.4254/wjh.v3.i7.198]
URL: https://www.wjgnet.com/1948-5182/full/v3/i7/198.htm
Number Citing Articles
1
Stefano Fagiuoli, Roberto Ravasio, Maria Grazia Lucà, Anna Baldan, Silvia Pecere, Alessandro Vitale, Luisa Pasulo. Management of hepatitis C infection before and after liver transplantationWorld Journal of Gastroenterology 2015; 21(15): 4447-4456 doi: 10.3748/wjg.v21.i15.4447
2
Geeta S. Karnik, Kirti Shetty. Management of Recurrent Hepatitis C in Orthotopic Liver Transplant RecipientsInfectious Disease Clinics of North America 2013; 27(2): 285 doi: 10.1016/j.idc.2013.02.003
3
A. A. Sukhoruk, E. V. Esaulenko. PHARMACOECONOMIC ASSESSMENT OF USING INTERFERON-FREE REGIMENS FOR CHRONIC HEPATITIS C AFTER LIVER TRANSPLANTATIONRussian Journal of Transplantology and Artificial Organs 2016; 18(2): 163 doi: 10.15825/1995-1191-2016-2-163-170
4
M. Palmer, R. Rubin, V. Rustgi. Randomised clinical trial: pre‐dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment‐naïve patients with chronic hepatitis C genotype 1Alimentary Pharmacology & Therapeutics 2012; 36(4): 370 doi: 10.1111/j.1365-2036.2012.05188.x